Agilent Technologies, Inc.
- Open
- 131.37
- Day high
- 132.83
- Day low
- 130.16
- Prev close
- 131.46
- Volume
- 2.4M
- Mkt cap
- $36.8B
- P/E (TTM)
- 26.1
- EPS (TTM)
- $4.99
- P/B
- 5.2
- P/S
- 5.1
- Yield
- 0.78%
- Per share
- $1.01
- ▼Insiders net selling -$217K over the last 3 months (0 open-market buys, 1 sale)
- 🏛Institutions mixed (13F)
Agilent Technologies, Inc. (A) is a Healthcare company listed on NYSE. The stock is up 18% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 1 sale (SEC Form 4).
Agilent Technologies, Inc. (A) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 11 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
A earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 27, 2026 | $1.41 | $1.49 | +5.7% | $1.8B | +2.0% |
| Feb 25, 2026 | $1.37 | $1.36 | -0.7% | $1.8B | -0.5% |
| Nov 24, 2025 | $1.58 | $1.59 | +0.4% | $1.8B | +0.4% |
| Aug 27, 2025 | $1.37 | $1.37 | +0.0% | $1.7B | +3.2% |
| May 28, 2025 | $1.26 | $1.31 | +4.0% | $1.7B | +2.5% |
| Feb 26, 2025 | $1.28 | $1.31 | +2.3% | $1.7B | +0.7% |
| Nov 25, 2024 | $1.41 | $1.46 | +3.5% | $1.7B | +1.7% |
| Aug 21, 2024 | $1.26 | $1.32 | +4.8% | $1.6B | +1.3% |
| May 29, 2024 | $1.19 | $1.22 | +2.5% | $1.6B | -0.6% |
| Feb 27, 2024 | $1.22 | $1.29 | +5.7% | $1.7B | +4.4% |
| Nov 20, 2023 | $1.34 | $1.38 | +3.0% | $1.7B | +6.4% |
| Aug 15, 2023 | $1.37 | $1.43 | +4.4% | $1.7B | -1.2% |
A insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 29, 2026 | KIRKWOOD JONAH PREVOSTofficer: Senior Vice President | Tax | 30 | $136.01 |
| Jun 5, 2026 | MCDONNELL PADRAIGdirector, officer: President and CEO | Tax | 418 | $137.40 |
| Jun 2, 2026 | Dolsten Mikaeldirector | Sell | 1,600 | $135.42 |
| May 21, 2026 | Buckner Michael Stevenofficer: Senior Vice President | Grant | 8,872 | — |
| May 12, 2026 | MAY SIMONofficer: Senior Vice President | Tax | 368 | $115.62 |
| Apr 2, 2026 | Henson Meghanofficer: Senior Vice President | Tax | 153 | $113.98 |
| Mar 23, 2026 | Anand Maladirector | Grant | 2,158 | $111.75 |
| Mar 23, 2026 | BRAWLEY OTIS Wdirector | Grant | 2,158 | $111.75 |
| Mar 23, 2026 | BRAWLEY OTIS Wdirector | Grant | 888 | $111.75 |
| Mar 23, 2026 | Rataj Sue H.director | Grant | 2,158 | $111.75 |
| Mar 23, 2026 | SCANGOS GEORGE Adirector | Grant | 1,057 | $111.75 |
| Mar 23, 2026 | Brown Judy Ldirector | Grant | 2,158 | $111.75 |
| Mar 23, 2026 | KOH BOON HWEEdirector | Grant | 2,158 | $111.75 |
| Mar 23, 2026 | Soriot Pascaldirector | Grant | 2,158 | $111.75 |
| Mar 23, 2026 | KOH BOON HWEEdirector | Tax | 648 | $111.75 |
Source: A SEC Form 4 filings, latest Jun 29, 2026. For informational purposes only — not investment advice.
See the full A insider & 13F page →Agilent Technologies, Inc. company profile
Overview
Agilent Technologies, Inc. (NYSE:A) is a leading scientific instrumentation and laboratory solutions company founded in 1999 as a spin-off from Hewlett-Packard Company. Headquartered in Santa Clara, California, Agilent has evolved into a global provider of analytical instruments, software, services, and consumables serving the life sciences, diagnostics, and applied chemical markets. The company operates through three primary business segments and serves customers across pharmaceutical, biotechnology, academic, government, environmental, forensic, food, and chemical industries worldwide.
Business
Agilent operates in the scientific instrumentation and analytical testing market, providing sophisticated laboratory equipment and services that help scientists analyze, identify, quantify, and test various substances and materials. The company's solutions are essential for drug discovery and development, quality control in manufacturing, environmental monitoring, food safety testing, and forensic analysis. The company operates through three main business segments: 1. **Life Sciences and Diagnostics Markets Group (LDG)** - approximately 40% of revenue: This segment provides liquid chromatography (LC) systems, liquid chromatography-mass spectrometry (LC-MS) systems, gas chromatography (GC) systems, and gas chromatography-mass spectrometry (GC-MS) systems. These instruments separate, identify, and quantify chemical compounds in samples. The segment also includes cell analysis systems, flow cytometers, real-time cell analyzers, and laboratory software for pharmaceutical research, clinical diagnostics, and academic research. 2. **Agilent CrossLab Group (ACG)** - approximately 42% of revenue: This is the services and consumables arm that provides ongoing support for laboratory operations. It includes GC and LC columns (the consumable parts that actually perform the separation), sample preparation products, laboratory supplies, maintenance services, training, compliance support, and software-as-a-service offerings. This segment generates recurring revenue from the installed base of instruments. 3. **Applied Markets Group (AMG)** - approximately 18% of revenue: This segment focuses on atomic spectroscopy instruments like inductively coupled plasma mass spectrometry (ICP-MS) and atomic absorption instruments, which analyze elemental composition of materials. It serves industries like environmental testing, food safety, metals analysis, and chemical manufacturing. The company also has a diagnostics and genomics business that produces DNA arrays for genetic testing, oligonucleotides (short DNA sequences used in research and diagnostics), and pathology reagents for cancer diagnosis.
Revenue model
Agilent generates revenue through multiple streams within its scientific instrumentation business model. The company sells high-value analytical instruments ranging from tens of thousands to hundreds of thousands of dollars, creating substantial upfront revenue. However, the business model's strength lies in its recurring revenue streams from consumables, services, and software subscriptions that generate ongoing cash flow from the installed instrument base. The primary revenue sources include instrument sales (one-time capital equipment purchases), consumables and supplies (ongoing purchases of columns, reagents, and sample preparation materials), service contracts (maintenance, training, and compliance support), and software subscriptions. Customers are primarily pharmaceutical and biotechnology companies, academic and government research institutions, environmental testing laboratories, food and beverage companies, and chemical manufacturers. Several factors influence Agilent's margins and profitability. Positive margin drivers include the company's pricing power due to high switching costs once customers invest in specific instrument platforms, the recurring nature of consumables and services revenue which typically carries higher margins than instruments, and operational leverage from the company's "Ignite" transformation program that centralizes procurement and flattens management structures. The company also benefits from exposure to high-growth markets like PFAS (per- and polyfluoroalkyl substances) testing, which has grown over 70% annually, and the expanding biopharmaceuticals market. Margin pressures come from competitive dynamics in mature instrument categories, customer budget constraints during economic downturns that delay capital equipment purchases, supply chain cost inflation, and geographic exposure to challenging markets like China, which represents a significant portion of revenue but has experienced volatility. Tariff impacts and currency fluctuations also affect profitability, though the company has implemented mitigation strategies including supply chain diversification and strategic pricing initiatives.
Competitive moat
Agilent possesses a moderate to strong competitive moat built primarily on high customer switching costs and technical expertise barriers. Once laboratories invest in Agilent's analytical instruments, they face significant switching costs including retraining personnel, revalidating analytical methods (which can take months and cost hundreds of thousands of dollars), and replacing consumables inventory. This creates substantial customer stickiness, particularly in regulated industries like pharmaceuticals where analytical methods must be approved by regulatory agencies. The company's moat is further strengthened by its comprehensive ecosystem approach, where instruments, consumables, software, and services work together seamlessly. Agilent's deep technical expertise in analytical chemistry, built over decades, creates barriers for new entrants who would need substantial R&D investment and time to develop comparable capabilities. The company's global service network and regulatory expertise in highly regulated markets also provide competitive advantages. However, the moat faces several challenges. Competition from established players like Thermo Fisher Scientific, Waters Corporation, and Shimadzu Corporation remains intense, particularly in mature instrument categories. Technological disruption poses a longer-term risk, as newer technologies or approaches could potentially replace traditional chromatography and mass spectrometry methods. Customer consolidation in the pharmaceutical industry gives large customers increased negotiating power, potentially pressuring pricing. Additionally, the cyclical nature of capital equipment purchases means that during economic downturns, customers can delay instrument replacements, affecting growth even with high switching costs. The strength of Agilent's moat varies by segment, with the highest switching costs in regulated pharmaceutical applications and lower barriers in more commoditized testing markets. Overall, while the moat provides meaningful protection, it requires continuous innovation and customer relationship management to maintain its effectiveness.
Risks & safety
Agilent demonstrates a **solid margin of safety** with strong financial fundamentals and manageable risk levels, though valuation metrics suggest limited upside at current prices. **Financial Strength:** - Cash position of $1.5 billion with minimal solvency risk - Current ratio of 2.1x indicating strong liquidity - Debt-to-equity ratio of 0.57x representing moderate leverage - Strong free cash flow generation of $318-388 million quarterly - Operating cash flow consistently positive at $221-481 million per quarter **Valuation Concerns:** - P/E ratio of 35.7x appears elevated for current growth rates - EV/EBITDA of 21.9x suggests premium valuation - Price-to-book ratio of 5.0x indicates market expects continued strong returns - Graham number analysis suggests potential overvaluation relative to intrinsic value **Other Considerations:** - Diversified revenue streams provide stability during market downturns - Recurring revenue from consumables and services (approximately 60% of total) offers predictable cash flows - Exposure to cyclical instrument replacement cycles creates earnings volatility - Geographic concentration risk in China and tariff exposure require monitoring
Recent development
Over the past few years, Agilent has undergone significant strategic transformation focused on operational efficiency and market positioning. The company launched its "Ignite" transformation program in 2024, which centralized procurement, implemented enterprise-wide pricing capabilities, flattened management layers, and enhanced digital capabilities. This initiative is expected to deliver $100 million in annualized cost savings and improve decision-making speed. Organizational restructuring has been a key focus, with Agilent transitioning from a technology-focused structure to a market-focused organization. The company consolidated its segments into three market-oriented groups: Life Sciences and Diagnostics Markets Group, Applied Markets Group, and Agilent CrossLab Group, enabling better customer alignment and market responsiveness. Strategic acquisitions have expanded capabilities in high-growth areas. The company acquired BIOVECTRA, a contract development and manufacturing organization specializing in oligonucleotides and CRISPR therapeutics, strengthening its position in the rapidly growing gene therapy market. Agilent also acquired Sigsense, an AI-powered lab optimization startup, enhancing its digital transformation capabilities. Product innovation has accelerated with launches including the Infinity III LC series featuring advanced automation, the Seahorse XF Flex analyzer for cellular metabolism research, and the InfinityLab Pro iQ series. The company has particularly focused on automation and digital integration to improve laboratory efficiency and reduce manual intervention. Market expansion efforts have concentrated on high-growth segments like PFAS testing (growing over 70% annually), advanced materials analysis, and biopharmaceutical applications. The company has also enhanced its e-commerce platform, achieving over $1 billion in digital orders for the first time, representing a significant shift toward digital customer engagement.
A company profile · for informational purposes only — not investment advice.
Track A with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free